Related Experiment Video
Updated: Jun 15, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Caffeine intake and dementia: systematic review and meta-analysis
Catarina Santos1, João Costa, João Santos
1Department of Hygiene and Epidemiology, Porto University Medical School, Porto, Portugal. catarinasantos@portugalmail.pt
Journal of Alzheimer'S Disease : JAD
|February 26, 2010
Summary
Caffeine intake shows a trend towards protecting against cognitive decline and dementia. However, more research is needed due to study variations.
Area of Science:
- Neuroscience
- Epidemiology
- Public Health
Background:
- Previous research, including a 2004 meta-analysis, indicated a link between coffee and reduced Alzheimer's risk.
- Numerous epidemiological studies have since been published, necessitating an updated analysis of caffeine's impact on cognitive health.
Purpose of the Study:
- To systematically review and meta-analyze published studies on the relationship between caffeine intake and cognitive decline or dementia.
- To update current understanding by synthesizing recent epidemiological evidence.
Main Methods:
- Systematic review and random-effects meta-analysis of cohort and case-control studies.
- Searched multiple databases (Medline, LILACS, Scopus, Web of Science) up to September 2009.
- Included nine cohort and two case-control studies examining Alzheimer's disease, dementia, or cognitive decline.
Main Results:
- The overall meta-analysis indicated a protective effect of caffeine intake, with a summary relative risk (RR) of 0.84 (95% CI: 0.72-0.99).
- Analysis of cohort studies alone yielded an RR of 0.93 (95% CI: 0.83-1.04).
- Excluding one influential study resulted in an RR of 0.77 (95% CI: 0.63-0.95), suggesting a stronger protective trend.
Conclusions:
- A trend towards a protective effect of caffeine against cognitive decline and dementia was observed.
- Significant methodological heterogeneity and a limited number of studies prevent definitive conclusions.
- Further high-quality epidemiological research is required to establish a robust association.
More Related Videos
Related Concept Videos
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:16Experimental Designs
An experimental design is a systematic process that allows researchers to evaluate the relationship between dependent and independent variables. There are three widely used types of experimental design - pre-experimental design, true experimental design, and quasi-experimental design. In pre-experimental design, the researcher compares the data before and after some interventions or treatments. The true-experimental design has more than one purposefully created group, a commonly measured...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...